Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity July 31, 2025
AAVantgarde Bio: A 38-year-old man regains his sight thanks to an innovative gene therapy, a world first. July 30, 2025
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks July 28, 2025
Newleos Therapeutics Appoints Stephen Brannan to Board of Directors and Announces NTX-1955 Clinical Progress in Generalized Anxiety Disorder July 24, 2025
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial July 15, 2025
